Eliminate the Confusion â€“ Annex 13 GMP guide (Pharmaceutical)
Venue: Online Event
|Event Date/Time: Jan 21, 2011||End Date/Time: Jan 21, 2011|
Areas Covered in the Seminar:
Review the role of the "Qualified Person" who must have access to the Product Specification File as the basis for assessment of the suitability for release and certification of a particular batch.
Packaging instructions requires expressly with a view to the complicated procedures in the manufacture of investigational medicinal products.
The requirement for reconciliation at the end of the packaging and labelling processes.
Packaging materials requires special quality control checks for a homogeneous appearance of the packs in order to prevent unintentional unblinding due to a visible difference between the placebo and the active medication packs.
Manufacturing operations that the production parameters and the corresponding in-process controls must be deduced from the knowledge actually available at the time.
An appropriate process of blinding the test preparation, comparator product and placebo must be completely identifiable.
The requirements for the randomisation procedure are also more strictly formulated: in addition, safety aspects and the procedure for breaking the code must be described in the corresponding procedures.
The section on the risks of product mix up in the case of simultaneous packaging of different preparations.
Labelling is specifically detailed in the draft e.g. name, address and telephone number of the sponsor, contract research organisation or the principal contact for the clinical trial.
Note: Use these promocode(117660) for 10% discount.